ATXI stock forecast
Our latest prediction for Avenue Therapeutics, Inc.'s stock price was made on the March 10, 2020 when the stock price was at 7.92$.
In the short term (2weeks), ATXI's stock price should underperform the market by -0.82%. During that period the price should oscillate between -10.79% and +14.24%.
In the medium term (3months), ATXI's stock price should underperform the market by -4.63%. During that period the price should oscillate between -41.73% and +33.65%.Get email alerts
Create a solid portfolio with ATXI
About Avenue Therapeutics, Inc.
Avenue Therapeutics, Inc. engages in acquiring, licensing, developing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, which is intended for the treatment of moderate to moderately severe post-operative pain. The company was founded on February 9, 2015 and is headquartered in New York, NY.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -1.69$ per share.
The book value per share is 1.23$
Three months stock forecastMarch 10, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|